|Title||Chief Physician, Professor, Director of ICU|
Prof. Ma Gang has been engaged in critical care medicine. He graduated from Clinical College at Chongqing Medical University in 1985 and was conferred upon the degree of Master of Medicine by Guangzhou Institute of Respiratory Disease in 1992.
Prof. Ma Gang mainly engages himself in clinical medicine, teaching and research of complication of cancer and has obtained profound achievements in cardiopulmonary resuscitation, respiratory therapy, stent implantation treatment and emergency care for malignant laryngotracheal stenosis and respiratory failure, early diagnosis of and treatment for postoperative fistula of esophagus cancer, supporting chemotherapy for critical diseases, application of bronchoscopy, and diagnosis and treatment of SIRS (systemic inflammatory response syndrome), sepsis, acute respiratory distress syndrome, severe infection and (MODS) multiple organ dysfunction syndrome.
Diagnosis and treatment of complication of cancer (engages himself in 4 research programs currently, published over 20 academic papers in core journals and participated in compilation of 2 monographs.
Prof. Ma graduated from Clinical College at Chongqing Medical University in 1985 and was conferred upon the degree of Master of Medicine by Guangzhou Institute of Respiratory Disease in 1992.
|Title||Associate chief physician|
Dr. Wang Daofeng is an associate chief physician in ICU of Sun Yat-sen University Cancer Center who graduated from Sun Yat-sen University and was conferred upon a master's degree and a doctoral degree. Deeply engaging himself in study and research on mechanism of development and growth of cancer, Doctor Wang is experienced in treatment for such symptoms during diagnosis of and for cancer as severe infectious shock, ARDS, MODS, postoperative anastomotic stoma fistula of esophagus cancer, laryngotracheal stenosis caused by cancer and acute tumor lysis syndrome as well as supporting treatment for cancer, reflecting deep understanding of such aspects; he conducts in-depth research on coagulation function of cancer patients before and after chemotherapy as well as operations by leading and assisting in scientific researches. He has published over 10 papers in Chinese and foreign authoritative journals. He has published over 10 papers in Chinese and foreign authoritative journals.
2 provincial scientific research programs relating to critical care for cancer (leading researcher), several research programs relating to cancer (participant)
He participates in associations, researches and studies relating to critical cancer diseases after obtaining the degree of Doctor of Critical Cancer Diseases.
|Publications||He has published over 10 papers relating to critical cancer diseases in Chinese and foreign journals.|
|Title||Associate chief physician, Associate Professor, Deputy Director of ICU|
Prof. Lou Ning has been engaged in critical care medicine, developing cardiovascular disease and renal disease treatment and supporting treatment of cancer patient.
07/2001-09/2001: Attending physician, Department of Cardiology of the Second Affiliated Hospital of Guangzhou Medical University
09/2001-04/2004: Research fellow, attending physician, Department of Nephrology of the First Affiliated Hospital, Sun Yat-sen University
2004-present: Chief physician, associate chief physician, ICU of Sun Yat-sen University Cancer Center
Critical care medicine; Cardiovascular disease and renal disease; Supporting treatment of cancer patient
09/1987-07/1993: Bachelor of Medicine in Clinical Medicine (6-year program), the First Military Medical University
09/1983-07/1996: Master of Medicine (Cardiovascular Molecular Biology)
09/1988-07/2001: Doctor of Medicine in Clinical Medicine (medical oncology focusing on cardiovascular disease)
1. Lou N, Chen Y, Zhou M. Inhibitory effect of polysaccharide krestin on foam cell formation and necrosis of murine peritoneal macrophages caused by oxidised low density lipoprotein. Med Sci Res, 1996, 24(1):49-51.
2. Lou N, Chen Y, Zhou M. Alterations in membrane fluidity, superoxide dismutase activity and lipoperoxide content in monocyte cell line U937 cultured with tertbutyl hydroperoxide in vitro. Med Sci Res, 1996, 24(4):225-227.
3. Lou N, Chen Y, Zhou M. Enhancement of antioxidative potential in heat, liver, spleen, kidney cells and erythrocytes of mice by polysaccharide krestin. Med Sci Res, 1996, 24(9):615-616.
4. Song LC, Chen HS, Lou N, Song C, Zeng J, Fu TH. Effect of Coriolus Versicolar Polysaccharide B on monocyte chemoatractant protein 1 gene expression in rat. Acta Pharmacol Sin, 2002, 23(6):539-543.
5. Zhou M, Chen Y, Lou N. The polysaccharide krestin prevents lipoperoxidative injury to experimental atherosclerotic rabbits. Med Sci Res, 1997, 25(3):137-140.
6. Chen Y, Zhou Mei, Lou N. The polysaccharide krestin prevents plaque formation in experimental atherosclerotic rabbits. Med Sci Res, 1997, 25(6):297-300.
7. Song LC, Song C, Zeng J, Xiong Ml, Lou N. Reduction in monocyte chemoattractant protein-1 mRNA expression in peripheral blood mononuclear cells of diamorphine addicts. Acta Pharmacol Sin 2002; 23(4):336-338.
8. Chen Y, Zhou M, Liu SX, Ding ZH, Lou N. Oxidative and malondialdehyde modification of ow-density lipoprotein: a comparative study. British J Biomed Sci, 1997; 54(3):159-165.
9. Chen Y, Zhou M, Guo ZG, Liu SX, Pang ZJ, Sun J, Lou N. Damage to macrophage by tert-butyl hydroperoxide and the protective action of the protein bound polysaccharide krestin. Med Sci Res, 1997; 25(9):601-606.
|Title||Associate Professor and Executive-Director|
Clinical Work began as a clinician in Beijing in Aug. 1988 in the China-Japan Friendship Hospital after graduating from the Sun Yat-sen University of medical sciences. As one of the earliest professional CCM (critical care medicine) doctors in China, Dr. Zhao got further training in the Dept. of Anesthesiology, Faculty of Medicine, University of Heidelberg since July 1976 and was awarded MD of CCM in Sept. 2000. Then Dr. Zhao went back to Guangzhou, China and worked continuously in ICU as CCM clinician in the Sun Yat-sen University Cancer Center until present.
From Sept. 1998 to Aug. 1999, Dr. Zhao was invited as visiting professor for scientific exchange in the Dept. of Molecular and Cellular Oncology and Immunology, MD Anderson Cancer Center, University of Texas. Dr. Zhao is professional expert in CCM work and administration. His PI team are now practicing modern clinical therapies and monitoring technique including hemodynamic monitoring, bedside emergent continuous renal replacement therapy (CRRT) therapy, mechanical ventilation and CPR manipulations skillfully in treating patients with severe infection, multiple organ dysfunction syndrome (MODS), sepsis, shock, DIC, circulatory/ respiratory/ renal failure, perioperative organ transplantation, sudden cardiac death, etc.
As director of the Dept. of Infection Control, Dr. Zhao is also in responsible for the Center’s administrative strategic prevention and clinical therapeutic treatment/consultation in cases of infection.
|Phone||+86 20 87343577 +86 20 87343335（Dept Hosp Infect）|
Research projects are mainly in the area of severe clinical infection，inflammatory dysfunction and MODS, esp. septic liver injury, and the respective clinical therapies, eg. continuous renal replacement therapy (CRRT) and anti-inflammatory drugs effects in patients with sepsis.Inflammatory mediators including oxygen and nitrogen free radicals, cytokines, adhesion molecules, some special enzymes and nuclear factors, and the PCD phenomenon were investigated.In addition, research is also performed to enhance hospital infection strategic administration and therapeutic control.
1996.7 -- 2000.9: Faculty of Medicine, University of Heidelberg, Germany (for clinical further training and graduate training in CCM, MD awarded);
1995.1 -- 1992.7: Goethe Institute in Beijing (for language, German MIII awarded).
1992.1 -- 1992.7: Basic Research Institute of the Chinese Academy of Medical Sciences in Beijing (science research technique training);
1982.9 -- 1988.7: Faculty of Medicine, Sun Yat-sen University of Medical Sciences (Medical BA and English Medicine Class Certificate awarded).
1. Qingyu Zhao*, Xiaodan Zhang, Yi Fang. Current Situation and Associated Factors of Withdrawing or Withholding Life Support to Patients in an Intensive Care Unit of Cancer Center in China. PLos One 2014;9(5);e98545.
2. Yi Fang, Qingyu Zhao, Gang Ma. Investigation on MDR1gene polymorphisms and its relationship with breast cancer risk factors in Chinese women. Med Oncol 2013;30;375-379.
3. Xiaodan Zhang, Qingyu Zhao*, Yi Fang, Guanxuan Chen, HF Zhang, Wenxiao Zhang , XP Yang. Effects of Perioperative Comprehensive Supportive Care Interventions on Outcome of Chinese Patients with Esophageal Carcinoma: a Prospective Study. Asian Pac J Cancer Prev. 2013;14(12):7359-66.
4. Jue Shen, Qingyu Zhao*, Baochun Gu, Wenfeng Ye. Assessment of nutritional status and application of nutritional support in 184 cancer patients with critical illness. Journal of Tropical Medicine 2014 ;14(1);52-55.
5. Jue Shen, Qingyu Zhao*, Yuchan Liang , Jiemei Zhu . Investigation and analysis of surgical site infections in cancer hospital. Chinese Journal of Nosocomiology 2013;23(20);4926-4928.
6. Shuqin Dai, Qi Zheng, Xingping Wu, Hongkai Su, Xinhua Xu, Qingyu Zhao*. The discordant results in serum through reverse syphilis screening algorithm. Chinese Journal of Hepatology 2013;34(10);1006-1009.
7. Yi Fang, Qingyu Zhao*, Dongfeng Huang, Shufang Guan, Jue Shen . The impact of exercise training on surgery tolerability in lung cancer patients with impaired pulmonary function. Chinese Journal of Physical Medicine and Rehabilitation 2013;28(7);619-623.
8. Jue Shen, Qingyu Zhao*. One case report on venous access port related blood stream infection with Stenotrophomonas maltophilia. Chinese Journal of Infection Control 2013;12(3);236-238.
9. Jue Shen, Baochun Gu, Lei Su, Qingyu Zhao*. Clinical significance of B-type natriuretic peptide in predicting outcomes of critically ill cancer patients. Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical care 2013;20(2);79-82.
10. Jue Shen, Xiaojun Lin, Bokang Cui, Qiuyao Zeng, Qingyu Zhao*. The protective effect of Xuebijing injection pretreatment on hepatic ischemia/reperfusion injury and eoagulopathy after excision of liver cancer. Chinese Critical Care Medicine 2013;25(12);743-748.
11. Chunyan Wu, Qingyu Zhao*. Research Progress on the drug resistance of S. maltophilia. International Journal of Laboratory Medicine 2012;33(8);956-958.
12. Wenxiao Zhang, Qingyu Zhao*. Roles of myeloid-derived suppressor cells in sepsis. International Journal of Pathology and Clinical Medicine 2012;32(6);546-549.
13. Zhibin Zhang, Zhonglian He, Miaoqing Mai, Qingyu Zhao*. Application Research of Infection Control Management System in Hospital. China Digital Medicine 2012;7(11);38-40.
14. Xiaodan Zhang, Qingyu Zhao*, Yuchan Liang , Jiemei Zhu . Clinical characteristics of nosocomial infections in tumor center during 2008－2010. Chinese Journal of Nosocomiology 2012;22(22);4995-4997.
15. Yuchan Liang , Qingyu Zhao*, Jiemei Zhu. Risk factors for occupational exposure of medical staff of tumor center in recent 5 years. Chinese Journal of Nosocomiology 2012;22(22);5052-5054.
16. Wenxiao Zhang, Yi Fang, Shuqin Dai, Zhongkai Wu, Qingyu Zhao*. Protective effects of polyenylphosphatidylcholine on rat septic model through peroxisome proliferator activated receptor γ. Chinese Journal of experimental surgery 2012;29(10);1966-1969.
17. Xiaodan Zhang, Qingyu Zhao*. Mechanism of the cholinergic anti-inflammatory pathway and its application in sepsis. International Journal of pathology and clinical medicine 2011;31(6);539-543.
18. Wenxiao Zhang, Qingyu Zhao*. Febrile neutropenic infection occurred in cancer patients undergoing autologous peripheral blood stem cell transplantation. Chinese Journal of Cancer Prevention and Treatment 2011;18(17);1398-1401.